PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer von Chabanon, Roman M, Muirhead, Gareth, Krastev, Dragomir B, Adam, Julien, Morel, Daphné, Garrido, Marlène, Lamb, Andrew, Hénon, Clémence, Dorvault, Nicolas, Rouanne, Mathieu, Marlow, Rebecca, Bajrami, Ilirjana, Cardeñosa, Marta Llorca, Konde, Asha, Besse, Benjamin, Ashworth, Alan, Pettitt, Stephen J, Haider, Syed, Marabelle, Aurélien, Tutt, Andrew Nj, Soria, Jean-Charles, Lord, Christopher J, Postel-Vinay, Sophie

Volltext

ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A von Williamson, Chris T., Miller, Rowan, Pemberton, Helen N., Jones, Samuel E., Campbell, James, Konde, Asha, Badham, Nicholas, Rafiq, Rumana, Brough, Rachel, Gulati, Aditi, Ryan, Colm J., Francis, Jeff, Vermulen, Peter B., Reynolds, Andrew R., Reaper, Philip M., Pollard, John R., Ashworth, Alan, Lord, Christopher J.

Volltext

Modeling Therapy Resistance in BRCA1/2 -Mutant Cancers von Dréan, Amy, Williamson, Chris T, Brough, Rachel, Brandsma, Inger, Menon, Malini, Konde, Asha, Garcia-Murillas, Isaac, Pemberton, Helen N, Frankum, Jessica, Rafiq, Rumana, Badham, Nicholas, Campbell, James, Gulati, Aditi, Turner, Nicholas C, Pettitt, Stephen J, Ashworth, Alan, Lord, Christopher J

Volltext

Genome-wide Profiling of Genetic Synthetic Lethality Identifies CDK12 as a Novel Determinant of PARP1/2 Inhibitor Sensitivity von BAJRAMI, Ilirjana, FRANKUM, Jessica R, CHEN, Lina, KOZAREWA, Iwanka, ASSIOTIS, Ioannis, FENWICK, Kerry, NATRAJAN, Rachael, LORD, Christopher J, ASHWORTH, Alan, KONDE, Asha, MILLER, Rowan E, REHMAN, Farah L, BROUGH, Rachel, CAMPBELL, James, SIMS, David, RAFIQ, Rumana, HOOPER, Sean

Volltext

ATR Is a Therapeutic Target in Synovial Sarcoma von Jones, Samuel E, Fleuren, Emmy D G, Frankum, Jessica, Konde, Asha, Williamson, Chris T, Krastev, Dragomir B, Pemberton, Helen N, Campbell, James, Gulati, Aditi, Elliott, Richard, Menon, Malini, Selfe, Joanna L, Brough, Rachel, Pettitt, Stephen J, Niedzwiedz, Wojciech, van der Graaf, Winette T A, Shipley, Janet, Ashworth, Alan, Lord, Christopher J

Volltext

CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours von Costa-Cabral, Sara, Brough, Rachel, Konde, Asha, Aarts, Marieke, Campbell, James, Marinari, Eliana, Riffell, Jenna, Bardelli, Alberto, Torrance, Christopher, Lord, Christopher J, Ashworth, Alan

Volltext

Correction: Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours von Costa-Cabral, Sara, Brough, Rachel, Konde, Asha, Aarts, Marieke, Campbell, James, Marinari, Eliana, Riffell, Jenna, Bardelli, Alberto, Torrance, Christopher, Lord, Christopher J, Ashworth, Alan

Volltext

Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours von Costa-Cabral, Sara, Brough, Rachel, Konde, Asha, Aarts, Marieke, Campbell, James, Marinari, Eliana, Riffell, Jenna, Bardelli, Alberto, Torrance, Christopher, Lord, Christopher J, Ashworth, Alan

Volltext

Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours von Costa-Cabral, Sara, Brough, Rachel, Konde, Asha, Aarts, Marieke, Campbell, James, Marinari, Eliana, Riffell, Jenna, Bardelli, Alberto, Torrance, Christopher, Lord, Christopher J, Ashworth, Alan

Volltext

PBRM1 Deficiency Confers Synthetic Lethality to DNA Repair Inhibitors in Cancer von Chabanon, Roman M, Morel, Daphné, Eychenne, Thomas, Colmet-Daage, Léo, Bajrami, Ilirjana, Dorvault, Nicolas, Garrido, Marlène, Meisenberg, Cornelia, Lamb, Andrew, Ngo, Carine, Hopkins, Suzanna R, Roumeliotis, Theodoros I, Jouny, Samuel, Hénon, Clémence, Kawai-Kawachi, Asuka, Astier, Clémence, Konde, Asha, Del Nery, Elaine, Massard, Christophe, Pettitt, Stephen J, Margueron, Raphaël, Choudhary, Jyoti S, Almouzni, Geneviève, Soria, Jean-Charles, Deutsch, Eric, Downs, Jessica A, Lord, Christopher J, Postel-Vinay, Sophie

Volltext

E-Cadherin/ROS1 Inhibitor Synthetic Lethality in Breast Cancer von Bajrami, Ilirjana, Marlow, Rebecca, van de Ven, Marieke, Brough, Rachel, Pemberton, Helen N, Frankum, Jessica, Song, Feifei, Rafiq, Rumana, Konde, Asha, Krastev, Dragomir B, Menon, Malini, Campbell, James, Gulati, Aditi, Kumar, Rahul, Pettitt, Stephen J, Gurden, Mark D, Cardenosa, Marta Llorca, Chong, Irene, Gazinska, Patrycja, Wallberg, Fredrik, Sawyer, Elinor J, Martin, Lesley-Ann, Dowsett, Mitch, Linardopoulos, Spiros, Natrajan, Rachael, Ryan, Colm J, Derksen, Patrick W B, Jonkers, Jos, Tutt, Andrew N J, Ashworth, Alan, Lord, Christopher J

Volltext

PBRM1 Deficiency Confers Synthetic Lethality to DNA Repair Inhibitors in Cancer von Chabanon, Roman, Morel, Daphné, Eychenne, Thomas, Colmet-Daage, Léo, Bajrami, Ilirjana, Dorvault, Nicolas, Garrido, Marlène, Meisenberg, Cornelia, Lamb, Andrew, Ngo, Carine, Hopkins, Suzanna, Roumeliotis, Theodoros, Jouny, Samuel, Hénon, Clémence, Kawai-Kawachi, Asuka, Astier, Clémence, Konde, Asha, del Nery, Elaine, Massard, Christophe, Pettitt, Stephen, Margueron, Raphaël, Choudhary, Jyoti, Almouzni, Geneviève, Soria, Jean-Charles, Deutsch, Eric, Downs, Jessica, Lord, Christopher, Postel-Vinay, Sophie

Volltext

Abstract 1058: Targeting chromatin remodeling-associated genetic vulnerabilities in cancer: PBRM1 defects are synthetic lethal with PARP and ATR inhibitors von Chabanon, Roman Merial, Morel, Daphné, Colmet-Daage, Léo, Eychenne, Thomas, Dorvault, Nicolas, Bajrami, Ilirjana, Garrido, Marlène, Hopkins, Suzanna, Meisenberg, Cornelia, Lamb, Andrew, Roumeliotis, Theo, Jouny, Samuel, Astier, Clémence, Konde, Asha, Almouzni, Geneviève, Choudhary, Jyoti, Soria, Jean-Charles, Downs, Jessica, Lord, Christopher J., Postel-Vinay, Sophie

Volltext

Abstract 2986: E-cadherin/ROS1 inhibitor synthetic lethality in breast cancer von Bajrami, Ilirjana, Marlow, Rebecca, Ven, Marieke van de, Brough, Rachel, Pemberton, Helen N., Frankum, Jessica, Song, Fei Fei, Rafiq, Rumana, Konde, Asha, Menon, Malini, Campbell, James, Gulati, Aditi, Kumar, Rahul, Pettitt, Stephen J., Gurden, Mark D., Cardenosa, Marta Llorca, Chong, Irene, Gazinska, Patrycja, Wallberg, Fredrik, Sawyer, Elinor J., Martin, Lesley-Ann, Dowsett, Mitch, Linardopoulos, Spiros, Ryan, Colm, Derksen, Patrick W., Jonkers, Jos, Tutt, Andrew N.J., Ashworth, Alan, Lord, Christopher J.

Volltext

Abstract 6094: Longitudinal analysis of PARP inhibitor and platinum resistance in BRCA1/2m breast cancer using liquid biopsy von Harvey-Jones, Elizabeth, Raghunandan, Maya, Robbez-Masson, Luisa, Thanussuyah, Alaguthurai, Liccardo, Roberta, Yablonovitch, Arielle, Cai, Mingyang, Drusbosky, Leylah, Dorschner, Michael, Pardo, Lorena Magraner, Marlow, Rebecca, Konde, Asha, Trendell, Jennifer, Alexander, John, Haider, Syed, Starling, Chris, Roxanis, Ioannis, Yen, Jennifer, Pettitt, Stephen J., Lord, Christopher J., Tutt, Andrew N.

Volltext

Abstract 2931: Cancer cells deficient in DNA mismatch repair (MMR) are selectively sensitive to inhibition of the DNA dependent protein kinase (DNA-PK) von Hewish, Madeleine, Fontebasso, Yari, Martin, Sarah A., Elliott, Richard, Perks, Kerry L., Konde, Asha, Bajrami, Ilirjana, Weverwijk, Antoinette Van, Cunningham, David, Lord, Christopher J., Ashworth, Alan

Volltext

Candidate drug therapies for molecularly defined subgroups of esophageal cancer identified from high-throughput drug screening von Chong, Irene Yu-Shing, Cunningham, David, Elliott, Richard, Konde, Asha, Campbell, James, Menon, Malini, Bowers, Leandra, Daley, Frances, Lord, Christopher J., Ashworth, Alan

Volltext